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In the Western world, peripheral vascular disease (PVD) has a high prevalence with high morbidity and mortality. In a large
percentage of these patients, lower limb amputation is still required. Studies of ischaemic skeletal muscle disclosed evidence
of endogenous angiogenesis and adaptive skeletal muscle metabolic changes in response to hypoxia. Chemokines are potent
chemoattractant cytokines that regulate leukocyte traﬃcking in homeostatic and inflammatory processes. More than 50 diﬀerent
chemokines and 20 diﬀerent chemokine receptors have been cloned. The chemokine stromal-cell-derived factor-1 (SDF-1
aka CXCL12) is a constitutively expressed and inducible chemokine that regulates multiple physiological processes, including
embryonic development and organ homeostasis. The biologic eﬀects of SDF-1 are mediated by chemokine receptor CXCR4, a 352
amino acid rhodopsin-like transmembrane-specific G protein-coupled receptor (GPCR). There is evidence that the administration
of SDF-1 increases blood flow and perfusion via recruitment of endothelial progenitor cells (EPCs). This review will focus on the
role of the SDF-1/CXCR4 system in the pathophysiology of PVD and discuss their potential as therapeutic targets for PVD.
1. Introduction
Atherosclerotic peripheral vascular disease (PVD) is a major
cause of morbidity and mortality in the Western world [1].
It has been reported to have 19.1% prevalence in those over
55 years of age [2], and 15% of male patients die within
5 years of diagnosis, with the deaths mostly due to other
associated atherosclerotic disease such as stroke, coronary
heart disease, and abdominal vascular disease [3]. With
an aging population and improved medical care that has
increased life expectancy, more patients are presenting with
critical leg ischemia (CLI), the end stage of PVD. In 10 to
40% of these patients [4], lower limb amputation may be
required because the anatomic extent and the distribution
of arterial occlusive disease make the patients unsuitable for
revascularization, despite current advances in surgery and
endovascular revascularization techniques.
In the past 20 years, rapid development in molecular
biology and understanding of mechanisms of angiogenesis
[5] have led to the development of therapeutic angiogenesis
as a promising strategy to treat a variety of cardiovascu-
lar diseases. Experimental animal model studies [6] have
progressed to several clinical trials which evaluated the
angiogenic potentials of growth factors such as hepatocyte
growth factor (HGF), vascular endothelial growth factor
(VEGF), and fibroblast growth factor (FGF) in inducing
new blood vessel growth in CLI patients. Unfortunately, the
results of these clinical trials have been inconsistent and
inconclusive. For example, in the regional angiogenesis with
VEGF (RAVE) trial [7], intramuscular adenoviral delivery of
VEGF in patients with unilateral exercise-limiting claudica-
tion had no eﬀects on primary eﬃcacy end points but was
associated with dose-dependent peripheral oedema. VEGF
induces formation of hyperpermeable and proinflammatory
vessels; the concerted actions of additional mediators (such
as the angiopoietins and platelet-derived growth factor) may
be required for their stabilization and maturation. This view
has been supported by the use of a combination of two
angiogenic factors, platelet-derived growth factor BB and
FGF-2, which synergistically induce vascular networks that
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remain stable for more than a year even after depletion of
angiogenic factors [8].
Chemokines are potent chemoattractant cytokines that
regulate leukocyte traﬃcking in homeostatic and inflam-
matory processes. More than 50 diﬀerent chemokines and
20 diﬀerent chemokine receptors have been cloned [9].
Chemokines usually bind tomultiple receptors, and the same
receptor may bind to more than one chemokine. However,
there is one exception to this rule: SDF-1, which binds
exclusively to CXCR4, and has CXCR4 as its only receptor
[9–16]. Recently, a new putative receptor called CXCR7 (aka
RDC1 and GPR159) for SDF-1 had been described [17];
however, its potential role in regulating cell traﬃcking awaits
confirmation by other laboratories.
This review will focus on the role of stromal-cell-
derived factor- (SDF-1), otherwise known as CXCL12, and
its receptor CXC chemokine receptor 4 (CXCR4; i.e., the
SDF-1/CXCR4 system) in the pathophysiology of PVD and
discuss their potential as therapeutic targets for PVD.
2. Stromal-Cell-Derived Factor- (SDF-1)
The chemokine stromal-cell-derived factor-1 (SDF-1, also
known as CXCL12) is a constitutively expressed and
inducible chemokine that regulates multiple physiological
processes, including embryonic development and organ
homeostasis [18]. SDF-1 is the only member of the α-
chemokines which does not possess the conserved Glu-Leu-
Arg motif, also called the ELR motif, preceding the first
cysteine residue but has angiogenic activity. Two main splice
forms of SDF-1 have been identified, SDF-1α and SDF-
1β, which have identical amino acid sequences except for
the presence of 4 additional amino acids at the carboxy
terminus of SDF-1β [19]. Another splice variant form, SDF-
1γ, has been subsequently identified in the nervous system
[20]. SDF-1δ, SDF-1ε, and SDF-1ϕ splice variants have been
described only recently in human tissues and are abundant
in the pancreas. Additionally, SDF-1ϕ and SDF-1ε are found
in the heart and liver, as well as in fetal and adult kidneys, but
the expression of SDF-1ϕ is more pronounced than SDF-1ε.
SDF-1δ, on the other hand, is also detected in the spleen, fetal
liver, and lungs [21].
SDF-1α is the predominant isoform found in all organs
but undergoes rapid proteolysis in blood. SDF-1β is more
resistant to blood-dependent degradation, stimulates angio-
genesis, and is present in highly vascularized organs such as
the liver, spleen, and kidneys. In contrast, SDF-1γ is located
in very metabolically active organs susceptible to infarction
such as the heart and the brain. The significance of the
existence of the splice forms of SDF-1 has largely remained
unclear. The understanding of the functional diversity of the
diﬀerent splicing variants will help in developing therapeutic
strategies. Structure-function analysis of SDF-1α (1–67) has
identified the NH2-terminal amino acids (residues 1–8) as
critical to receptor binding and activation. The expression of
SDF-1 in several organs including liver, brain, kidney, and
heart increased in the presence of ischaemia [22]. Recently,
it has been shown that SDF-1 expression in skeletal muscle
is also elevated in ischaemic skeletal muscle fibres of patients
with critical leg ischaemia [23]. Studies at the molecular level
show that the SDF-1 promoter contains hypoxia inducible
factor-1α (HIF-1α) binding sites, as revealed by chromatin
immunoprecipitation analysis, and SDF-1 expression is
upregulated in endothelial cells by HIF-1α [24]. Thus, it
is possible that elevated levels of HIF-1α in critical leg
ischaemia [25] may have led to increased SDF-1 in the
ischaemic skeletal muscle fibres.
3. CXCR4
The biologic eﬀects of SDF-1 are mediated by the chemokine
receptor CXCR4. CXCR4 (aka fusin and CD184), is a
352 amino acid rhodopsin-like transmembrane specific G
protein-coupled receptor (GPCR). CXCR4 is expressed by
various cell lines, including muscle cell lines, endothelial
cells, leucocytes, and progenitor cells [26–28] and the
expression of CXCR4 receptor on endothelial cells has
been reported to be regulated by hypoxia [29, 30] at
transcriptional level. The regulation of CXCR4 can also
occur during protein expression when it is subjected to a
number of cotranslational modifications. These processes
aﬀect the expression and function of the receptor [31].
After expression, CXCR4 is exposed to proteolytic degra-
dation by proteases that are present in the haematopoietic
microenvironment and serum (e.g., cathepsin G, elastase,
dipeptidyl-peptidase) [32, 33]. CXCR4 after interaction with
SDF-1 is internalized from the surface in a mechanism
involving G-protein-coupled receptor kinases followed by
the binding of β-arrestin [34], and subsequently, is recircu-
lated from the endosomal compartment at diﬀerent rates:
this achieves another level of regulation. The function of
the CXCR4 receptor depends on its incorporation into
membrane lipid domains called lipid rafts and several signals
from other membrane receptors (e.g., G-protein-coupled
C3a anaphylatoxin receptor—C3aR) or integrins that may
increase the incorporation of CXCR4 into membrane lipid
rafts, enhancing its signalling [35, 36]. Finally, CXCR4
is the subject of negative regulation by regulators of G-
protein signalling (RGS) proteins whichmay regulate CXCR4
signalling diﬀerently in diﬀerent tissues [37, 38].
4. SDF-1 CXCR4 Signalling Axis
Upon activation of CXCR4, a number of signalling pathways
are activated leading to a variety of biological responses. As
CXCR4 couples to the Gi family of proteins, pertussis toxin
(PTX), which ADP-ribosylates Gαi and inhibits GPCR/Gi
coupling, has been used to delineate pathways that are G-
protein-dependent and -independent. Strong evidence exists
that the protein-tyrosine phosphatases SHIP1 and SHIP2,
as well as membrane-expressed hematopoietic phosphatase
CD45, are involved in the modulation of CXCR4 signalling
[39]. CXCR4 signalling is negatively regulated by the RGS
proteins [37, 38] and lipid phosphatase activity of tumor
suppressor phosphatase and tensin homolog (PTEN) [40].
4.1. G Protein Signalling. To date, the majority of signalling
pathways and biological outcomes of CXCR4 activation
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are PTX sensitive and, therefore, dependent on activation
of Gi proteins. Activated Gi is able to inhibit adenylyl
cyclase as well as activate the Src family of tyrosine
kinases while liberated Gβγ activates phospholipase C-β
(PLC-β) [31], phosphoinositide-3 kinase (PI3K) [41], and
mitogen activated protein kinase (MAPK) [42] signalling
pathways. As described earlier, the CXCR4/SDF-1 complex
is incorporated into lipid rafts and may associate with
members of the Src family of kinases [43]. Activated CXCR4
increases intracellular calcium mobilization and induces
phosphorylation of focal adhesion components such as FAK
and Pyk2 [44–46]. The PI3K/AKT and MAPK signal trans-
duction pathways contribute to chemotaxis, cell migration
[42, 47], and secretion of various matrix metalloproteinases
(MMP’s) including MMP-2 and MMP-9 [46, 48]. MMP-2
andMMP-9 are involved in themigration of cells through the
basement membrane [49]. They also induce secretion of the
angiopoietic factor, VEGF [50]. Furthermore, blocking either
the PI3K or MAPK pathway inhibits CXCR4-activated cell
migration in a pre-B cell line [42]. Ultimately, through these
pathways, SDF1-bound CXCR4 can induce cell proliferation,
chemotaxis, migration, the secretion of angiopoietic factors,
all important components of the angiogenic process [51].
4.2. G Protein Independent Signalling. Activation of the
JAK/STAT pathway by CXCR4 has been proposed to be
G protein independent [52]. SDF-1 induces the transient
association of JAK2 and JAK3 with CXCR4, leading to
the activation and nuclear translocation of a number of
STAT proteins. While JAK/STAT activation is G protein-
independent, pretreatment with PTX leads to a prolonged
association of JAK with CXCR4 suggesting that G protein
coupling is involved in JAK/STAT-receptor complex recycling
[52].
5. SDF-1, Vasculogenesis, and Angiogenesis
Until recently, new blood vessel growth in the adult was
thought to occur exclusively through angiogenesis, defined as
the sprouting of vessels from existing vascular structures. In
contrast to angiogenesis, endothelial progenitor cells (EPCs)
are mobilised from the bone marrow and recruited to foci of
neovascularization where they form new blood vessels in situ
through a process called vasculogenesis. Once thought to be
limited to embryonic development, vasculogenesis appears
to be preserved in the adult and contributes to postischemic
vascular regeneration.
5.1. The Eﬀect of SDF-1 and Endothelial Progenitor Cell (EPC)
Traﬃcking on Vasculogenesis. In 1997, Asahara et al. reported
the isolation of putative EPC from human peripheral
blood, on the basis of cell-surface expression of CD34 and
other endothelial markers [53]. These cells are reported to
diﬀerentiate in vitro into endothelial cells and seem to be
incorporated at sites of active angiogenesis in various animal
models of ischaemia. These findings suggest that incorpo-
ration of bone-marrow-derived endothelial precursor cells
into the new vessels lumen contributes to the growing vessels
and complements the resident endothelial cells in sprouting
new vessels. Also, ischaemia and various cytokines, includ-
ing VEGF and granulocyte-macrophage colony-stimulating
factor (GM-CSF), are reported to mobilize EPC into sites of
neovascularization [54]. EPCs express CXCR4 which allows
homing to sites of neovascularization in ischaemic tissues
which release the homing signal, that is, SDF-1, which then
act as ligand for CXCR4. Other CXCR4+ proangiogenic cells
are composed of immature and mature hematopoietic cells,
and smooth muscle cell (SMC) progenitors, which all have
direct or indirect proangiogenic properties.
SDF-1 is upregulated in ischaemic tissues as hypoxic
and/or apoptotic conditions are triggers to the induction
of cytokine and chemokine expression. Ceradini et al. have
demonstrated that SDF-1 expression in ischaemic sites is
directly correlated with the amplitude of hypoxia [24]. Sig-
nalling activated by hypoxia leading to SDF-1 upregulation
involves the recruitment of integrin-linked kinase and HIF-
1 [24, 55]. Acute and gradual arterial occlusion can both
lead to increased SDF-1 expression in ischaemic limb [56].
However, the expression of SDF-1 can be aﬀected by age, with
decreased expression in older age [57]. We investigated the
expression of twomain splice variant, SDF-1α and SDF-1β in
ischaemic human skeletal muscle of patients with critical leg
ischaemia [23]. The study confirms the elevated expression
of SDF-1α but there is lack of SDF-1β expression in ischaemic
human skeletal muscle. It is postulated that the lack of SDF-
1β expression in critical leg ischaemiamay be explained by its
transient expression [58] because all the muscles examined
have been chronically ischaemic. Another human study [59]
shows that SDF-1 expression increases in acute on chronic
ischaemia with perivascular retention of CXCR4+ cells.
The increased expression of SDF-1 in ischaemic muscles
acts as a chemoattractant and homing signal for CXCR4+
EPCs. Locally administered SDF-1 has been shown to
augment the accumulation of EPCs to the site of ischaemia,
resulting in enhancing the eﬃcacy of neovascularization
after systemic EPC transplantation [60]. The study pro-
vided experimental proof of principle for the feasibility
and therapeutic eﬀectiveness of local administration of
SDF-1 in augmenting the SDF-1/CXCR4+ EPCs enhanced
neovascularization in ischaemic muscles.
5.2. Angiogenic Properties of SDF-1. Many critical cell func-
tions such as migration, proliferation, and apoptosis inhi-
bition are regulated by SDF-1. There are limited studies in
the literature investigating human microvascular endothelial
cells which are better representatives of the microvasculature
involved in angiogenesis. In a study comparing the angio-
genic properties of both SDF-1α and SDF-1β splice variants
[23], both splice variants attenuate human microvascular
endothelial cells apoptosis and stimulate cell proliferation
and capillary tube formation in a Matrigel assay. The
Matrigel assay mimics various steps in angiogenesis such as
proliferation, migration, and diﬀerentiation in the process
of capillary tube formation. Compared with SDF-1α, SDF-
1β has a greater eﬀect on apoptosis and cell proliferation.
Treatment with both variants results in time-dependent
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activation of PI3K/Akt and MAPK p44/42 but not p38 MAP
kinase [23]. These properties are likely to contribute to the
complex mechanism of angiogenesis.
6. Potential Use of SDF-1 as
Therapeutic Angiogenic Factor
The ideal mode of delivery of angiogenic growth factors
has yet to be determined. They are usually delivered by
gene transfer, which commonly uses adenoviruses (Ads) and
plasmids as vectors or delivered as recombinant protein.
Each method has its own disadvantages [6] and the delivery
of SDF-1 is no exception. Recently, two promising studies
attempt to provide successful modes of SDF-1 delivery in
ischaemic limbs to improve revascularisation using vascular
gene transfer of SDF-1 by ultrasound-mediated destruction
of plasmid bearing microbubbles and mutated recombinant
SDF-1 proteins [61, 62].
The success of EPCs therapy relies on the ability of cells
to repair damaged tissue, and it is critically dependent on
the homing, migration, and retention to sites of ischaemia,
regardless of mode of delivery. In an animal model of chronic
ischaemic limb, it has been demonstrated that a noninvasive
gene- and cell-based therapeutic approach, using vascular
gene transfer of SDF-1 by ultrasound-mediated destruction
of plasmid bearing microbubbles to augment homing and
engraftment of exogenously administered EPCs, leads to a
greater angiogenic response as compared to SDF-1 gene
therapy or intravenous EPCs alone [61]. However, long-term
data on EPC engraftment, beyond 14 days after delivery, are
not available.
The use of SDF-1 protein therapy to enhance angio-
genesis is hampered by concerns regarding rapid inac-
tivation of the chemokine in the protease-rich environ-
ment of the ischaemic limb. SDF-1 processing by matrix
metalloproteinase-2 results in generation of a neurotoxic
fragment that does not bind to its main receptor, CXCR4,
and lacks chemotactic activity for EPCs [63, 64]. To ensure
sustained SDF-1 activity in the hostile environment of the
ischaemic limb, Segers et al. [62] designed recombinant SDF-
1 proteins carrying mutations that provide resistance to pro-
tease cleavage. One of these SDF-1 variants, SSDF-1(S4V),
is resistant to processing by matrix metalloproteinase-2 and
dipeptidyl peptidase IV but retains chemotactic activity in
vitro and induced angiogenesis in vivo. Delivery of protease-
resistant SDF-1 with the use of self-assembling nanofibres
to achieve sustained local concentrations increases arteriolar
density and enhances blood flow in the ischaemic mouse
hindlimb.
Similar to treatment with the angiogenic growth factors
basic fibroblast growth factor (FGF) and VEGF, admin-
istration of protease-resistant SDF-1 augments perfusion,
increasing vascular density in the ischaemic limb. Consider-
ing the established eﬀects of VEGF and basic FGF admin-
istration in enhancing experimental ischaemic angiogenesis,
what additional role could SDF-1 treatment play? Compared
with the eﬀects of other angiogenic growth factors, SDF-1 has
unique properties. Generation of hyperpermeable vessels,
a major characteristic of VEGF-stimulated angiogenesis,
may not be observed after injection of SDF-1. SDF-1
contributes to the stabilization of neovessel formation by
recruiting CXCR4+PDGFR+ckit+ smooth muscle progeni-
tor cells during recovery from vascular injury [65]. However,
the angiogenic pathways involving VEGF and SDF-1 are
not independent. Extensive evidence suggests that SDF-1
upregulates VEGF synthesis in several diﬀerent cell types,
whereas VEGF and basic FGF induce SDF-1 and its receptor
CXCR4 in endothelial cells [66]. In a transgenic system of
VEGF-mediated neovascularization, SDF-1 is a key mediator
of retention of recruited bone-marrow-derived cells in close
proximity to angiogenic vessels [67]. These interactions
provide a link between angiogenic growth factors and
chemokine-induced angiogenesis.
Although promising, the use SDF-1 in a clinical setting
is uncertain and yet to be tested. The animals used for
experimentation are typically young and healthy and have
the same genetic background. In contrast, patients with PVD
are a highly heterogeneous group comprising older individ-
uals with enormous genetic diversity and various comorbid
conditions, such as diabetes mellitus, hypertension, and
hyperlipidemia.
7. Future Work
Better understanding of the mechanisms of action of the
chemokine in the ischaemic limb is necessary for optimal
exploitation of the SDF-1/CXCR4 axis in PVD. As discussed,
SDF-1 not only exerts its eﬀect on vasculogenesis by the
recruitment of CXCR4+ progenitor cells, but it also has
direct angiogenic properties on endothelial cells. The mecha-
nism of actions causing neovascularisation in ischaemic limb
is uncertain: one or both of the processes may be involved. In
addition, there is uncertainty on the role and interaction of
VEGF and other angiogenic growth factors with SDF-1 in the
microenvironment of ischaemic limbs. The answers to these
issues are paramount to understanding the interplay between
various mediators of angiogenesis and to design therapeutic
strategies combining protein and cell therapy approaches.
Moreover, the eﬀects of SDF-1 on the inflammatory
response in the ischaemic limb need to be understood. The
roles of elevated expression of SDF-1 and its interaction
with other angiogenic growth factors in ischaemic muscles
need to be determined. There has been no study on how
the increased expression of SDF-1 by ischaemic muscles
aﬀect serum levels of SDF-1, which can then aﬀect the
mobilisation of progenitor cells from bonemarrow. Evidence
from in vivo studies in models of inflammatory injury is
conflicting, suggesting that SDF-1 exerts context-dependent
proinflammatory and antiinflammatory actions [68].
The role of SDF-1 in establishing long-term stable and
mature blood vessels remains unknown. A major limiting
factor in angiogenic therapies is the formation of unstable
vessels that may rapidly regress after cessation of treatment
[69]. Whether SDF-1 mediates coating of the neovessels with
pericytes and vascular maturation is not known. Formation
of viable and stable neovessels in vivo may require the
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concerted eﬀort of several distinct mediators. Finally, much
work is needed to investigate the role of the newly discovered
SDF-1 receptor CXCR7 on SDF-1 angiogenic properties.
To apply SDF-1 treatment in patients with PVD, certain
issues will need to be considered, such as the eﬀect of
SDF-1 on atherosclerosis. Additional experiments using
atherosclerotic animal models may shed light on this con-
cern. Nevertheless, we believe that the concept of augmenting
local accumulation of transplanted EPCs opens perspectives
for the clinical strategy of EPC therapies.
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